BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia
The following press release was obtained from BridgeBio.com, parent company of QED therapeutics. To learn more about QED and its research surrounding achondroplasia and other skeletal dysplasias, click here. –…